Focus: Angitia is a Series C+ biopharmaceutical company focused on bispecific antibody therapeutics for neurology and musculoskeletal disorders. The company operates as a clinical-stage biotech with a lean footprint headquartered in Woodland Hills, CA.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
2 added, 5 removed. Backfill posture.
Angitia offers high-risk, high-upside career opportunity best suited for those seeking equity exposure and clinical-stage impact, but limited hiring velocity and R&D focus suggest evaluate management execution carefully.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Angitia Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Angitia Biopharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Biopharma bites: Angitia, LB Pharma raise funds, plus Eisai-Henlius deal and CVS formulary updates - FirstWord Pharma
Biopharma bites: Angitia, LB Pharma raise funds, plus Eisai-Henlius deal and CVS formulary updates FirstWord Pharma
Angitia raises $130M to challenge Amgen with bone-building bispecifics - Fierce Biotech
Angitia raises $130M to challenge Amgen with bone-building bispecifics Fierce Biotech
Angitia gets $130M Series D for pipeline of musculoskeletal drugs - Endpoints News
Angitia gets $130M Series D for pipeline of musculoskeletal drugs Endpoints News
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles